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Background: Estimating the incidence of medical conditions using claims data often requires constructing a
prevalence period that predates an event of interest, for instance the diagnosis of cancer, to exclude those with
pre-existing conditions from the incidence risk set. Those conditions missed during the prevalence period may be
misclassified as incident conditions (false positives) after the event of interest.
Using Medicare claims, we examined the impact of selecting shorter versus longer prevalence periods on the
incidence and misclassification of 12 relatively common conditions in older persons.
Methods: The source of data for this study was the National Cancer Institute’s Surveillance, Epidemiology, and End
Results cancer registry linked to Medicare claims. Two cohorts of women were included: 33,731 diagnosed with
breast cancer between 2000 and 2002, who had ≥ 36 months of Medicare eligibility prior to cancer, the event of
interest; and 101,649 without cancer meeting the same Medicare eligibility criterion. Cancer patients were followed
from 36 months before cancer diagnosis (prevalence period) up to 3 months after diagnosis (incidence period).
Non-cancer patients were followed for up to 39 months after the beginning of Medicare eligibility. A sham date
was inserted after 36 months to separate the prevalence and incidence periods. Using 36 months as the gold
standard, the prevalence period was then shortened in 6-month increments to examine the impact on the number
of conditions first detected during the incidence period.
Results: In the breast cancer cohort, shortening the prevalence period from 36 to 6 months increased the
incidence rates (per 1,000 patients) of all conditions; for example: hypertension 196 to 243; diabetes 34 to 76;
chronic obstructive pulmonary disease 29 to 46; osteoarthritis 27 to 36; congestive heart failure 20 to 36;
osteoporosis 22 to 29; and cerebrovascular disease 13 to 21. Shortening the prevalence period has less impact on
those without cancer.
Conclusions: Selecting a short prevalence period to rule out pre-existing conditions can, through misclassification,
substantially inflate estimates of incident conditions. In incidence studies based on Medicare claims, selecting a
prevalence period of ≥24 months balances the need to exclude pre-existing conditions with retaining the largest
possible cohort.
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Medicare administrative and claims data have many uses
[1], including estimating the overall incidence of chronic
and acute conditions [2-13], as well as the incidence of
adverse events related to medical interventions [14-17]
or within certain care settings [18]. Since information on
medical history is not generally available in Medicare
data - with some exceptions where claims are linked to
other data sets [7,18] – researchers interested in estimat-
ing disease incidence, especially chronic disease inci-
dence, often divide the observation period into two
discrete intervals: a prevalence period, in which patients
already diagnosed with the condition are identified and
excluded from the incident condition risk set; and an in-
cidence period, which is then searched for claims indi-
cating the presence of previously undetected conditions
[2,3,6,8,11,12,15]. In studies where one is interested in
the incidence of conditions that follow a specific clinical
event, such as the diagnosis of cancer, the onset of end-
stage renal disease, or a medical or surgical intervention,
the date of diagnosis or intervention typically is used to
define the end of the prevalence period and the begin-
ning of the incidence period [3,4,15]. Researchers then
look backwards from that date a specific number of
months or years to define the prevalence period, and ei-
ther they require that all patients included in the study
have at least that amount of time under observation
prior to that date [3,15], or they use all of the data back
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prevalence period on the classification of a patient condition into one of fo
and incidence periods; condition present in prevalence period only; condit
prevalence nor incidence periods. (Left-hand box) P indicates that that con
incidence. I indicates the condition is incident. The incidence is calculated
either the prevalence or incidence period. Increasing the prevalence period
prevalent. Patients with the condition present in the incidence period only
prevalence and incidence periods (upper arrow within upper right-hand bo
incidence period can be reclassified as having the condition in the prevale
move in the opposite direction when the prevalence period is shortened (a “sham” index date may be selected to indicate the be-
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period of observation [2,6,8,11,12], for instance 12
months of Medicare eligibility.
Selecting the length of the prevalence period often en-
tails a tradeoff between A) sample-size, which tends to
be larger with shorter prevalence periods, especially
when dates of diagnosis or intervention defining the end
of the prevalence period are distributed throughout a
block of data defined by a calendar period [3,4,15], and
B) the ability to identify and exclude patients with pre-
existing conditions from the incidence risk set. If one
considers the entire observation period (prevalence
period and incidence period combined), then each indi-
vidual can fall into one of four mutually exclusive groups
for each condition of interest: condition is present in
both the incidence and prevalence periods; condition is
present only in the incidence period; condition is present
only in the prevalence period; and condition is present
in neither the prevalence nor the incidence period.
Lengthening the prevalence period may reassign pa-
tients: first, from the “neither” group to the “prevalence
only” group; second, from the “incidence only” group to
the “both” group. Shortening the prevalence period will
have the opposite effect (Figure 1).
In theory, one could pick a sufficiently long prevalence
period such that the “incidence only” group would in-
clude only true positives, assuming, of course, perfect
sensitivity and specificity for the information used toDirection of 
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additional lengthening of the prevalence period will not
result in any additional reclassifying of “incidence only”
patients as “both prevalence and incidence” patients, or
in their removal from the incident risk set. Conversely,
shortening the prevalence period from this point would
add false positives to the true positives in the “incidence
only” group. Adding false positives naturally would in-
flate incidence estimates. Furthermore, it could, in the-
ory, increase type II error in studies of risk factors for
the conditions, or studies on the outcomes of the
conditions.
The objective of this study was to examine the impact
of changing the length of the prevalence period on




The source of data for this study was the National Cancer
Institute’s (NCI) Surveillance, Epidemiology, and End Re-
sults (SEER) cancer registry linked to Medicare claims
[19]. SEER contains cancer incidence and survival data
from population-based cancer registries throughout the
United States, presently covering approximately 28% of
the population [20]. In SEER-Medicare, cancer registry
data are linked to Medicare enrollment and claims data,
which are available for 93% of those aged ≥ 65 years in the
SEER registry [21]. Claims available in SEER-Medicare in-
clude hospital short- and long-stay, skilled nursing facility,
physician/supplier, institutional outpatient, home health
agency, and durable medical equipment. Our dataset also
included a separately created 5% random sample of non-
cancer patients from the Medicare program in the same
catchment areas as those in the SEER program.
Inclusion criteria
Two cohorts, cancer and non-cancer, were included in
the study. The cancer cohort consisted of women diag-
nosed with breast cancer between January 1, 2000, and
December 31, 2002, who had at least 36 months of
Medicare Part A (hospital) and Part B (outpatient) fee-
for-service coverage prior to the diagnosis of cancer.
Medicare and other sources of administrative and claims
data also are used to examine the epidemiology of dis-
ease in patients without cancer. Patterns of incidence
misclassification could differ between those with cancer
and others in the general population, due to shared risk
factors and also detection bias associated with diagnostic
work-up for cancer and cancer treatment. Thus, for
comparison, we also included in this study a cohort of
Medicare beneficiaries who had not been diagnosed with
cancer. The non-cancer cohort consisted of all women
in the sample who reached a total of at least 36 monthsof Medicare Part A and Part B fee-for-service cove-
rage during the same time period (January 1, 2000, and
December 31, 2002). Therefore, the calendar intervals
defining the prevalence and incidence periods were iden-
tical in the cancer and non-cancer cohorts.
Observation period
Patients in the cancer cohort were followed from 36
months before to up to three months after the date of
diagnosis. Since SEER provides only the month and year
of diagnosis, the first day of the month was used as the
date of diagnosis. Patients in the non-cancer cohort were
assigned a “sham” index date on the first day of the 37th
month after the beginning of Medicare Part A and B
coverage. The observation period was divided into two
periods. The prevalence period consisted of 36 months
prior to cancer diagnosis or the sham index date. The
incidence period consisted of three months following
cancer diagnosis or the sham index date.
Patients and variables
Patients in both cohorts were described according to
age, race/ethnicity, SEER region, and NCI Comorbidity
Index score [22,23]. Additional variables from SEER, in-
cluding cancer stage, grade, estrogen and progesterone
receptor status, and year of diagnosis, were used to de-
scribe the cancer cohort.
International Classification of Diseases, 9th Edition,
Clinical Modification (ICD-9-CM) codes [24] within
Medicare claims were used to identify 12 common
chronic and acute conditions in the elderly, consisting of
diabetes, hypertension, congestive heart failure, chronic
obstructive pulmonary disease (COPD), cerebrovascular
disease, renal disease, osteoarthritis, myocardial infarc-
tion, depression, osteoporosis, liver disease, and hip frac-
ture. (Table 1) Diagnoses recorded on claims for
inpatient stays were counted at the time of their first oc-
currence. Diagnoses in outpatient facility and physician
claims were assessed similarly to the NCI Comorbidity
Index algorithm, which requires two diagnoses at least
30 days apart to identify a condition (taking the first oc-
currence as the date of onset).
Analysis
For each condition, each patient in each cohort was
assigned to one of four mutually exclusive groups based
on when the condition was identified: in both the preva-
lence and incidence periods; in the prevalence period only;
in the incidence period only; and in neither the prevalence
nor the incidence period. The 36-month prevalence period
was used to exclude previously diagnosed patients to per-
mit the identification of the incident cases (and to calcu-
late the incidence of each condition). This analysis was
considered the “gold standard” for comparing other
Table 1 International classification of diseases, 9th edition, clinical modification (ICD-9-CM) codes used to identify
conditions




Congestive heart failure ICD-9-CM
diagnosis








296.2x, 296.3x, 298.0, 300.4, 309.0, 309.1, 309.28, 311
Diabetes ICD-9-CM
diagnosis









571.2, 571.4-571.49, 571.5, 571.6, 571.8, 571.9, 572.2-572.8, 456.0-456.21, V42.7
Myocardial infarction ICD-9-CM
diagnosis









285.21, 403.xx-404.xx, 405.01, 405.11, 405.91, 458.21, 582.xx, 583.xx, 585, 586, 588.xx, 593.71-
593.73, V42.0
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patients considered to be “true positives”.
The length of the prevalence period was then reduced
in 6-month increments from 30 months to only 6
months before cancer diagnosis or the sham date.
Patients were reassigned to one of the four groups for
each of the prevalence periods. Shortening the preva-
lence period meant that some patients in the prevalence
only group might move to the neither group, and those
in the prevalence and incidence group might move to
the incidence only group. (Figure 1) For each prevalence
period (30, 24, 18, 12, and 6 months), we recalculated
the incidence and the number of patients added to the
incidence only group as a result of shortening the preva-
lence period. Patients added to the incidence only group,
as an artifact of shortening the prevalence period, were
classified as false positives, and for each shorter preva-
lence period we calculated (A) the false positive fraction,
which was defined as the number of false positives in
the incidence period divided by the number of condi-
tions identified in the “gold standard” 36-month preva-
lence period, and (B) the percent of all incident cases
that were false positives. Since all patients classified as
incident cases using a 36-month prevalence period also
were classified as incident cases using shorter prevalence
periods, the “sensitivity” of using shorter prevalenceperiods (probability of being classified as an incident
condition using a shorter prevalence period given
one was classified as an incident condition using the
36-month prevalence period) =1 for all the shorter
prevalence periods. However, the specificity (probability
of not being classified as an incident condition using a
shorter prevalence period given one was not classified as
an incident condition using the 36-month prevalence
period) declines with shorter prevalence periods, causing
the false positive fraction to increase and the positive
predictive value to decrease.
The epidemiology of conditions, as well as patterns of
misclassification, could differ between the cancer and
non-cancer cohorts based on shared risk factors for con-
ditions and cancer, and also that cancer is likely to result
in the increased detection (detection bias) of pre-
existing, but previously undiagnosed conditions. There-
fore, these two cohorts were analyzed separately.
This study was conducted as part of a protocol sub-
mitted to Quorum Review Institutional Review Board.
On November 10, 2011, Quorum granted a determin-
ation of exemption for this protocol, based on the fact
that the information in the data files is recorded in such
a manner that subjects cannot be identified either dir-
ectly or through identifiers linked to them. The Quorum
Review File # for the exemption determination is 26648.
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There were 33,731 cancer and 101,649 non-cancer pa-
tients. Characteristics are described in Table 2. Based on
the 36-month prevalence period, incidence proportions
per 1,000 patients ranged from 196.3 for hypertension to
1.0 for liver disease in the cancer cohort, and from 13.1
for hypertension to 0.2 for liver and renal disease in the
non-cancer cohort (Table 3). Prevalence proportions also
were higher for cancer patients, although the differences
between the two cohorts were not as large.
The incidence of all conditions increased in both the
cancer (Figure 2) and non-cancer (Figure 3) cohorts as
the prevalence period was shortened in 6-month incre-
ments from 36 to 6 months. For example, in cancer

































aAge at diagnosis index date.
bCalifornia includes Los Angeles, San Francisco/Oakland, San Jose/Monterey, and Gr
c1,888 non-cancer patients had no region reported.
dComorbidity index based on conditions identified in the 12 months prior to the dito 243; diabetes 34 to 76; COPD 29 to 46; osteoarthritis
27 to 36; congestive heart failure 20 to 36; osteoporosis
22 to 29; cerebrovascular disease 13 to 21; depression 14
to 18; and myocardial infarction 13 to 17. Patterns were
similar in the cancer and non-cancer cohorts, with the
biggest increases in incidence when the prevalence
period was shortened from 12 months to 6 months.
In the cancer cohort false positive fractions for the
prevalence period of 6 months ranged from 0.44 for dia-
betes and hypertension to 0.02 for hip fracture and <0.01
for pancreatitis. False positive fractions declined rapidly be-
tween prevalence periods of 6 and 12 months, and more
slowly thereafter. (Figure 4) Patterns of false positive frac-
tions were similar, but an order of magnitude smaller, in
the non-cancer cohort (Figure 5).non-cancer patient cohorts
Breast cancer Non-cancer
patients patients
N = 33,731 (%) N = 101,649 (%)
5,498 (16.3) 27,783 (27.3)
9,618 (28.5) 29,883 (29.4)
8,903 (26.4) 24,098 (23.7)
9,712 (28.8) 19,885 (19.6)
29,487 (87.4) 85,329 (83.9)
2,173 (6.4) 7,483 (7.4)
1,016 (3.0) 6,317 (6.2)
1,055 (3.1) 2,520 (2.5)
) 1,009 (3.0) 3,575 (3.5)
10,533 (31.2) 30,910 (30.4)
2,121 (6.3) 6,380 (6.3)
442 (1.3) 1,712 (1.7)
2,397 (7.1) 7,172 (7.1)
2,889 (8.6) 8,680 (8.5)
2,355 (7.0) 6,920 (6.8)
2,638 (7.8) 8,029 (7.9)
5,950 (17.6) 15,961 (15.7)
717 (2.1) 2,751 (2.7)
851 (2.5) 3,006 (3.0)
nd) 1,829 (5.4) 4,665 (4.6)
27,193 (80.6) 76,804 (75.6)
3,965 (11.8) 18,087 (17.8)






Table 3 Incidence and prevalence proportions of conditions in breast cancer and non-cancer cohorts
Incidenceaproportion Prevalencea proportion
Condition Breast cancer Non-cancer Breast cancer Non-cancer
Cerebrovascular disease 13.1 3.1 55.1 33.0
Chronic obstructive pulmonary disease 28.6 2.7 66.1 34.0
Congestive heart failure 19.8 2.8 76.9 32.1
Depression 14.2 1.5 35.1 21.1
Diabetes 33.5 3.4 91.1 46.8
Hip fracture 3.7 1.1 17.3 10.6
Hypertension 196.3 13.1 319.8 161.2
Liver disease 1.0 0.2 2.9 1.5
Myocardial infarction 12.7 2.0 34.8 23.1
Osteoarthritis 27.4 4.6 83.8 58.0
Osteoporosis 22.4 2.2 40.7 23.1
Renal disease 2.2 0.2 8.0 2.9
a Both incidence and prevalence proportions reported as /1,000 patients at risk. Incidence period was 3 months after the date of cancer diagnosis (cancer
patients) or sham date (non-cancer patients). Prevalence period was 36 months before the date of cancer diagnosis (cancer patients) or sham date
(non-cancer patients).
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betes and hypertension cases identified using a 6-month
prevalence period were misclassified as false positives
(Figure 6), because they would have been excluded as
prevalent cases had the prevalence period been 36 months.
Based on a prevalence period of 6 months, false positive
incident cases comprised more than 20% of the total inci-
























Figure 2 Incidence of conditions by duration of the prevalence perio
period used to exclude patients with the condition prior to cancer diagnos
axis. Hypertension rates (/1,000) are as follows: 6 months 343.4; 12 months
36 months 196.3.misclassification occurred when the prevalence period was
lengthened from 6 to 12 months. Patterns of misclassifica-
tion were similar in the non-cancer cohort, but misclassifi-
cation occurred at lower rates (Figure 7).
Discussion
Uses of Medicare administrative and claims data include












d – breast cancer cohort. The prevalence period is the observation
is. Hypertension is not shown to avoid compression of the vertical




































Figure 3 Incidence of conditions by duration of the prevalence period – non-cancer cohort. The prevalence period is the observation
period used to exclude patients with the condition prior to sham index date. Hypertension is not shown to avoid compression of the vertical




































Figure 4 False Positive Fractions* – breast cancer cohort. A false positive fraction is defined as the number of false positives in the incidence
period divided by the number of conditions identified in the “gold standard” 36-month prevalence period.



































Figure 5 False Positive Fractions* – non-cancer cohort. A false positive fraction is defined as the number of false positives in the incidence


















































Figure 6 Proportion of false positive incident conditions – breast cancer cohort. The prevalence period is the observation period used to
exclude patients with the condition prior to cancer diagnosis.



















































Figure 7 Proportion of false positive incident conditions – non-cancer cohort. The prevalence period is the observation period used to
exclude patients with the condition prior to the sham diagnosis date.
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using claims to identify adverse events related to treat-
ment [14-17], and this interest may well strengthen with
the availability of Medicare Part D oral drug data, and as
the United States Food and Drug Administration explores
new data structures and methodologies for identifying and
analyzing adverse drug events [25]. Many such analyses
require that the investigator define a prevalence period to
exclude patients with pre-existing conditions from the in-
cidence risk set [2,3,6,8,11,12,15]. In this study, we sought
to understand how changing the duration of the preva-
lence period, and specifically shortening it from a “gold
standard” of 36 months, would affect the incidence esti-
mates for 12 chronic and acute conditions common
among the elderly. We found that the number of false
positive incident cases increased considerably as the
length of the prevalence period was shortened. Using a
6-month prevalence period, false positives accounted for
more than 50% of all incident hypertension and diabetes
cases in the cancer cohort, and there were also high false-
positive rates in the non-cancer cohort.
Our findings suggest that studies using relatively short
prevalence periods to exclude pre-existing disease from
the incident risk set may overestimate the incidence of the
condition because the risk set includes false positive (un-
detected) prevalent cases. This may be especially prob-
lematic in studies that estimate trends in the annual
incidence of conditions where the prevalence also isincreasing - namely chronic conditions like diabetes,
where we observed the greatest increase in false positive
incident cases associated with shortening the prevalence
period. To minimize potential misclassification when re-
peat acute conditions are classified as prevalent (false-
negative), it is critical to use disease-specific algorithms to
distinguish follow-up care from new events. For example,
a six month lag between two hip fracture claims would be
likely to represent two separate incident fractures rather
than chronic care for a single fracture [26].
We constructed our cancer cohort from SEER-
Medicare, and used the date of cancer diagnosis to div-
ide the observation period into prevalence and incidence
periods. Researchers using SEER-Medicare for epide-
miologic studies typically require only 12 months of
Medicare Part A and Part B coverage prior to cancer
diagnosis to calculate an NCI Comorbidity Index
[22,23]. In studies on the incidence of conditions, pos-
sibly including adverse-events related to cancer treat-
ment where a comparator group is not included [15],
the look-back period used to define the NCI Comorbid-
ity Index also doubles as the prevalence period for ex-
cluding pre-existing conditions. Our findings show that
with a 12-month prevalence period, false positives
accounted for 20-30% of all incident diabetes, hyperten-
sion, congestive heart failure, COPD, cerebrovascular
disease, and renal disease cases in cancer patients.
Therefore, establishing a prevalence period based on
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Index could result in overestimating the incidence of
conditions at the time of cancer diagnosis by up to 30%.
Also, diluting the true positive incident cases with false
positives could mask underlying associations between in-
cident conditions and other variables. Consequently, it is
advisable for researchers to consider longer prevalence
periods if they are using SEER-Medicare to investigate
the incidence of conditions, especially chronic condi-
tions, that occur around the time of cancer diagnosis.
However, this should be weighed against the loss of sam-
ple size that can result from requiring patients to have
longer periods of Medicare Part A and B coverage prior
to cancer diagnosis.
The differences between the cancer and the non-
cancer cohort deserve comment. It is difficult to com-
pare these populations directly because, in the cancer
cohort, certain comorbid conditions may also be associ-
ated with cancer. Hence, one should not expect the
same prevalence or incidence estimates in both cohorts,
even with adjustment for age and other common con-
founders. Despite this, it is instructive to see how much
larger the incidence rates are for most conditions in the
cancer cohort (i.e., on the order of 3–15 times higher).
Most likely, this is due to the diagnostic workup as part
of the diagnosis of cancer and/or treatment planning –
“detection bias” - suggesting that studies of cohorts
undergoing a sentinel event (like breast cancer or myo-
cardial infarction) may find additional comorbid condi-
tions after the index event. Whether these should be
considered as “baseline” comorbid conditions is some-
thing to be considered, and would depend on the condi-
tion and the importance of identifying the condition in
the study.
Our study has several limitations. First, we defined a
36-month prevalence period as the gold standard for de-
fining true positive incident cases. It is possible that had
we used a longer prevalence period, some of the true
positive incident cases would have been excluded from
the risk set, having also appeared in the additional
prevalence period. Extending the prevalence period can
only reduce, not increase, the number of incident cases.
Therefore, selecting a shorter rather than longer gold
standard can only result in under-estimating the number
of false positives. In this regard, our study may present
conservative estimates of misclassification.
Second, we selected cohorts that only included patients
with 36 months of Medicare Part A and B coverage prior
to cancer diagnosis (cancer cohort) or the sham date
(non-cancer cohort). This was necessary to identify true
positive incident cases in a stable cohort. As discussed
above, in reality, cohort sizes would increase as the re-
quired prevalence period gets shorter. This, in turn, could
affect the incidence of the conditions we studied.Third, we included only 12 conditions that are rela-
tively common in older patients. Many are included in
the NCI Comorbidity Index, and others are of interest
as they could result from cancer interventions, or they
could directly or indirectly influence cancer outcomes.
In order for conditions to be defined as false positives in
the incident analysis, they had to have been present in
both the 36-month prevalent and incident periods, but
then to drop out of the prevalent period as it became
shorter. This may best describe chronic conditions with
diagnoses that appear only infrequently in claims but
then become relevant for medical decision-making
around the time of cancer diagnosis. Patterns of mis-
classification for other conditions may differ from the
ones we included in this study. Similarly, different defi-
nitions of these chronic conditions, i.e., the use of dif-
ferent ICD-9 codes or different thresholds for the
number, timing, or type of claims, may give different
results.
Fourth, we elected to divide the observation period
into prevalence and incidence periods based on the date
of cancer diagnosis. However, to the extent that diagnos-
tic work-up for cancer begins prior to diagnosis, and
that this results in increased detection of new condi-
tions, changing the point at which the prevalence period
ends and the incidence period begins could affect the in-
cidence rates and the amount of misclassification. As
with most studies based on SEER-Medicare, Medicare
claims, or other sources of administrative and claims
data, we did not include a “true gold standard” with per-
fect sensitivity and specificity for ascertaining the preva-
lences and incidences of the conditions. Finally, our
cancer cohort included only women with breast cancer.
It is possible that patterns of misclassification could dif-
fer in other types of cancers.Conclusions
Estimating the incidence of medical conditions using
claims data often requires constructing a prevalence
period that predates an event of interest to exclude those
with pre-existing conditions from the incidence risk set.
Our findings show that selecting a short prevalence
period can, through misclassification, substantially in-
flate incidence estimates. This is especially problematic
with chronic conditions like diabetes. Selecting longer
prevalence periods will mitigate this problem. Based on
our findings, we recommend a prevalence period of ≥24
months, especially if the focus of the incidence analysis
is on estimating the incidence of chronic conditions that
may appear less frequently in Medicare claims. However,
this decision should be weighed against the associated
loss of sample size and the need to include patients of
younger age.
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